Branded

CAMBRIDGE, Mass. — More than three-quarters of patients with multiple sclerosis using a drug made by Sanofi subsidiary Genzyme did not experience disease relapse for two years, according to results of a late-stage clinical trial revealed over the weekend.

The drug maker announced Saturday results of the "CARE-MS I" trial, the first of two phase-3 clinical trials comparing the investigational drug Lemtrada (alemtuzumab) with Pfizer's and EMD Serono's Rebif (interferon beta-1a) in patients with relapsing-remitting MS.

BRIDGEWATER, N.J. — A drug made by Coria Labs for treating acne now is available in a convenient, ready-to-use pump, the drug maker said Monday.

Coria announced the availability of the Acanya Gel (clindamycin phosphate and benzoyl peroxide) pump in the 1.2%/2.5% strength for acne vulgarism.

The drug is the only Food and Drug Administration-approved once-daily combination of an antibiotic and benzoyl peroxide for treating inflammatory and non-inflammatory acne, the company said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for treating a severe form of epilepsy, the agency said Monday.

The FDA announced the approval of Onfi (clobazam) tablets, made by Catalent Pharma Solutions and Lundbeck, as an add-on treatment for seizures associated with Lennox-Gastaut syndrome in patients ages 2 years and older. The agency gave the drug orphan drug designation because the disease affects fewer than 200,000 people in the United States.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a new formulation of a testosterone therapy made by Watson Pharmaceuticals, the drug maker said Friday.

Watson announced the approval of its Androderm (testosterone) transdermal system in the 2-mg and 4-mg formulation. The company said the new smaller size and lower-dose patch would provide "highly effective" testosterone administration with a 20% reduction in the active ingredient from the original strength. Watson plans to launch the new patch next month.

BOSTON — This year’s jump in measles in the United States and Canada was costly and occurred among unvaccinated children and adults, suggested several studies being presented at the 49th Annual Meeting of the Infectious Diseases Society of America here Thursday.

WASHINGTON — Two senators are trying to get the Joint Select Committee on Deficit Reduction to take up a bill that would ban so-called "pay-for-delay" patent settlements between brand and generic drug companies, according to published reports.

The Pharma Letter reported that Sens. Herb Kohl, D-Wis., and Chuck Grassley, R-Iowa, had urged the "super committee" to support a bill that would ban settlements that include any form of payment in exchange for holding off launch of a generic drug.

SWIFTWATER, Pa. — Sanofi Pasteur, the vaccines division of Sanofi, released data from a new study examining the ability of its Fluzone High-Dose vaccine to provoke an immune response in elderly and younger adults, compared with a standard dose of Fluzone vaccine.

"The results further support the immunogenicity advantages of Fluzone High-Dose vaccine as compared to Fluzone vaccine, the standard dose comparator, in seniors 65 years of age and older," stated Peter Tsang, director clinical development, Sanofi Pasteur.

ATLANTA — More than 1-in-10 Americans ages 12 years and older take antidepressants, and the rate of antidepressant use in the United States among all ages increased 400% between 1988 and 2008, according to a new report by the Centers for Disease Control and Prevention's National Center for Health Statistics.